Diagnostic Center | August 15, 2024
ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
The clinical trial will be conducted at 19 sites with 10,335 participants across India
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Subscribe To Our Newsletter & Stay Updated
